Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.

Journal: The Lancet. Oncology
Published Date: May 1, 2019

Abstract

BACKGROUND: The Response Assessment in Neuro-Oncology (RANO) criteria and requirements for a uniform protocol have been introduced to standardise assessment of MRI scans in both clinical trials and clinical practice. However, these criteria mainly rely on manual two-dimensional measurements of contrast-enhancing (CE) target lesions and thus restrict both reliability and accurate assessment of tumour burden and treatment response. We aimed to develop a framework relying on artificial neural networks (ANNs) for fully automated quantitative analysis of MRI in neuro-oncology to overcome the inherent limitations of manual assessment of tumour burden.

Authors

  • Philipp Kickingereder
    From the Department of Radiology (D.B., P.S., J.P.R., P.K., K.Y., M.F., H.P.S.), Division of Medical Image Computing (S.K., M.G., N.G., K.H.M.H.), Division of Statistics (M.W.), and Department of Medical Physics (T.A.K., F.D.), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany (D.B., H.P.S., K.H.M.H.); and Departments of Urology (J.P.R., B.H., M.H., B.A.H.) and Neuroradiology (P.K.), University of Heidelberg Medical Center, Heidelberg, Germany.
  • Fabian Isensee
  • Irada Tursunova
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Jens Petersen
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany; Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ulf Neuberger
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • David Bonekamp
    From the Department of Radiology (D.B., P.S., J.P.R., P.K., K.Y., M.F., H.P.S.), Division of Medical Image Computing (S.K., M.G., N.G., K.H.M.H.), Division of Statistics (M.W.), and Department of Medical Physics (T.A.K., F.D.), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany (D.B., H.P.S., K.H.M.H.); and Departments of Urology (J.P.R., B.H., M.H., B.A.H.) and Neuroradiology (P.K.), University of Heidelberg Medical Center, Heidelberg, Germany.
  • Gianluca Brugnara
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Marianne Schell
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Tobias Kessler
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Martha Foltyn
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Inga Harting
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Felix Sahm
    Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Marcel Prager
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Martha Nowosielski
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
  • Antje Wick
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany.
  • Marco Nolden
    Medical Imaging Components, Division Medical Image Computing, DKFZ Heidelberg, Germany.
  • Alexander Radbruch
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jürgen Debus
    Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany.
  • Heinz-Peter Schlemmer
    From the Department of Radiology (D.B., P.S., J.P.R., P.K., K.Y., M.F., H.P.S.), Division of Medical Image Computing (S.K., M.G., N.G., K.H.M.H.), Division of Statistics (M.W.), and Department of Medical Physics (T.A.K., F.D.), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany (D.B., H.P.S., K.H.M.H.); and Departments of Urology (J.P.R., B.H., M.H., B.A.H.) and Neuroradiology (P.K.), University of Heidelberg Medical Center, Heidelberg, Germany.
  • Sabine Heiland
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Michael Platten
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany.
  • Andreas von Deimling
    Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Martin J van den Bent
    Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Thierry Gorlia
    European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Wolfgang Wick
    Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Martin Bendszus
    Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Klaus H Maier-Hein
    Medical Image Computing (MIC), German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: k.maier-hein@dkfz.de.

Keywords

External Resources

Popular Topics
Recent Journals